Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells - Trial NCT03046407
Access comprehensive clinical trial information for NCT03046407 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Chinese Academy of Sciences and is currently status unknown. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
retinal pigment epithelium transplantation
Interventional
biological
Sponsor & Location
Chinese Academy of Sciences
Timeline & Enrollment
Early Phase 1
Sep 06, 2017
Dec 01, 2020
Primary Outcome
safety and tolerance of transplantation
Summary
This project intends to transplant human embryonic stem cells derived retinal pigment
 epitheliums into subretinal space of patients to treat dry age-related macular
 degeneration(dry-AMD).And we will assess the safety and efficacy of RPE transplants to treat
 dry AMD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03046407
Non-Device Trial